Article
Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.
Molecular cancer therapeutics - 4 Feb 2026
Pulido Ines, Gunder Laura C, Ying Chenghao, Wang Yaya, Dai Yan, Yang Zimo, Rahnama Alireza, Li Jinhua, Sun Yuetong, Liu Chuhe, Zhou Haoxin, Wang Guoqiang, Foley Kevin P, Abdelhady Khaled, Massad Malek G, Prince Thomas L, Papautsky Ian, Ying Weiwen, Shimamura Takeshi
Abstract excerpt
KRAS G12D is a common oncogenic driver mutation in diverse cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. KRASG12D inhibitors have recently progressed into clinical trials but will likely face innate or acquired drug resistance similar to that which has been observed for KRASG12C inhibitors, such as activation of receptor tyrosine kinases, KRAS independence, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.